Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

细胞因子释放综合征 嵌合抗原受体 免疫疗法 癌症研究 B细胞 抗原 抗体 耐火材料(行星科学) T细胞 CD19 淋巴瘤 封锁 单克隆抗体
作者
Elise A. Chong,Jakub Svoboda,Sunita Dwivedy Nasta,Daniel Jeffrey Landsburg,Nicole Winchell,Ellen B. Napier,Anthony R. Mato,Jan Joseph Melenhorst,Marco Ruella,Simon Francis Lacey,Carl H. June,Stephen J. Schuster
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 4198-4198 被引量:83
标识
DOI:10.1182/blood-2018-99-119502
摘要

Abstract Introduction: Chimeric antigen receptor modified T cells directed against CD19 (CART19) achieve durable remissions in about 30-40% of relapsed or refractory (r/r) diffuse large B cell lymphoma (DLBCL); this led to recent FDA approvals of tisagenlecleucel (Schuster NEJM 2017, Schuster ASH 2017) and axicabtagene ciloleucel (Neelapu NEJM 2017). Despite this, about two-thirds of pts will not achieve a durable remission and there remains a need for effective therapies for these pts. CAR T cell exhaustion and an immunosuppressive tumor-microenvironment are considered possible causes of CAR T cell failure. Pembrolizumab, an anti-PD1 immune checkpoint inhibitor, is an attractive option following CAR T-cell therapy to reverse T cell exhaustion (Chong, Blood 2017). In this trial, pembrolizumab was administered to pts with B-cell lymphomas (NHL) with progressive or relapsed disease at various points in time after CART19, including during early progression (non-responders) or late relapse after CART19. Thus, this study provides important insights into the timing and ability of pembrolizumab to stimulate CAR T cells. Methods: This prospective single-institution trial enrolled pts with progressive or relapsed NHL after treatment with CART19 expressing either a murine (CTL019) or a humanized (CTL119) CD19-specific single chain antibody fragment fused in tandem with 4-1BB and CD3ζ costimulatory / activation domains (NCT02650999). Pts who received intervening therapy between CART19 infusion and screening were excluded. Pts received fixed dose pembrolizumab 200mg IV every 3 weeks until progression of disease, therapy limiting-toxicity, or elective protocol discontinuation. The primary endpoint was safety. Secondary endpoints included clinical outcomes. Results: From June 1, 2016 to June 4, 2018, 12 pts who received CART19 for r/r NHL on other clinical trials (NCT02030834; NCT02445248) were enrolled with progressive disease (N=8) or relapse (N=4) following CART19. 11 pts had DLBCL [4 germinal center (3 "double/triple hit"), 4 non-germinal center;1 T-cell rich DLBCL; 1 transformed FL; 1 primary mediastinal B-cell lymphoma] and 1 pt had follicular lymphoma (FL). Median age was 58 years (range: 30-78 years). Median number of prior therapies was 4 (range 3-8). Median PFS after CART19 was 2.2 months (range: 0.4-3.2 months); median time to first pembrolizumab dose was 3.3 months (range: 0.4-42.8 months). After pembrolizumab, adverse events (CTCAE 4.0) per patient at least possibly related were: neutropenia (grade 3/4; N=3), cytokine release syndrome (grade 3 on Penn scale; N=1), infusion reaction (grade 2; N=1), fever (grade 1/2; N=2), fatigue (grade 1/2; N=2), pleural effusion (grade 1, N=1), arthralgia (grade 1; N=1). One patient developed CMV infection (unrelated; grade 4) resulting in discontinuation of protocol therapy. Eleven pts are evaluable for response. Best ORR after pembrolizumab was 27% [1 complete response (CR); 2 partial response (PR)]; 1 pt had stable disease, and 7 pts had progressive disease. One patient with germinal center DLBCL continues in CR at 20 months; one patient with T-cell rich DLBCL in PR was removed from study because of CMV pneumonitis. 9/12 pts showed a re-expansion peak in peripheral blood CART19 cells (CART19 transgene copy number) after the first pembrolizumab dose between days 2 and 14 (median 3 days). Maximum CAR transgene copy number during therapy did not correlate with response; however, responding pts had more than one re-expansion peak during pembrolizumab while non-responding pts had only a single re-expansion peak or no expansion following the initial dose of pembrolizumab. Of the 3 pts without CART19 post-pembrolizumab expansion, 2 pts had relapsed disease after sustained CR following CART19 and 1 pt was CART19 refractory. Conclusions: PD1 blockade with pembrolizumab appears safe and results in clinical responses in a subset of pts with progression of NHL after anti-CD19 directed CART cell therapy. Analysis of the pharmacokinetics of CAR T-cells in pts treated with pembrolizumab appears to identify responding pts and supports the hypothesis that, in some pts, CAR T cells expand following PD1 blockade. Additional studies examining the immunophenotype of CAR T cells in detail are in progress and will be presented. Disclosures Chong: Novartis: Consultancy. Svoboda:Regeneron: Research Funding; Kyowa: Consultancy; Merck: Research Funding; Seattle Genetics: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; TG Therapeutics: Research Funding; KITE: Consultancy; Pharmacyclics: Consultancy, Research Funding. Dwivedy Nasta:Debiopharm: Research Funding; Incyte: Research Funding; Pharmacyclics: Research Funding; Rafael/WF: Research Funding; Takeda/Millenium: Research Funding; Roche: Research Funding; Merck: Other: DSMC; Aileron: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees. Landsburg:Curis: Consultancy, Research Funding; Takeda: Consultancy. Mato:TG Therapeutics: Consultancy, Research Funding; Celgene: Consultancy; Acerta: Research Funding; AstraZeneca: Consultancy; Portola: Research Funding; Regeneron: Research Funding; Medscape: Honoraria; AbbVie: Consultancy, Research Funding; Pharmacyclics, an AbbVie Company: Consultancy, Research Funding; Prime Oncology: Honoraria; Johnson & Johnson: Consultancy. Melenhorst:Incyte: Research Funding; Parker Institute for Cancer Immunotherapy: Research Funding; Shanghai UNICAR Therapy, Inc: Consultancy; novartis: Patents & Royalties, Research Funding; Casi Pharmaceuticals: Consultancy. Ruella:University of Pennsylvania: Patents & Royalties. Lacey:Parker Foundation: Research Funding; Tmunity: Research Funding; Novartis Pharmaceuticals Corporation: Research Funding; Novartis Pharmaceuticals Corporation: Patents & Royalties. June:Celldex: Consultancy, Membership on an entity's Board of Directors or advisory committees; Tmunity Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Immune Design: Membership on an entity's Board of Directors or advisory committees; Tmunity Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Novartis Pharmaceutical Corporation: Patents & Royalties, Research Funding; Novartis Pharmaceutical Corporation: Patents & Royalties, Research Funding; Immune Design: Membership on an entity's Board of Directors or advisory committees. Schuster:Novartis Pharmaceuticals Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Dava Oncology: Consultancy, Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy, Honoraria, Research Funding; Nordic Nanovector: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
共享精神的应助被weddcf采纳,获得10
刚刚
蔓越莓发布了新的文献求助10
刚刚
cloudss发布了新的文献求助10
1秒前
1秒前
sevenseven完成签到,获得积分10
1秒前
1秒前
zhouzhou完成签到 ,获得积分10
1秒前
甜美冰旋完成签到,获得积分10
1秒前
斯文败类的应助被FeCl采纳,获得10
2秒前
nannan完成签到,获得积分10
2秒前
现代的东蒽完成签到,获得积分10
2秒前
脑洞疼的应助被Duxize采纳,获得10
2秒前
爆米花的应助被1820采纳,获得10
3秒前
start发布了新的文献求助10
3秒前
人生如梦完成签到,获得积分10
3秒前
海猫食堂完成签到,获得积分10
4秒前
4XXXX完成签到,获得积分10
4秒前
4秒前
5秒前
5秒前
微笑发布了新的文献求助10
5秒前
AnZeng完成签到,获得积分10
5秒前
天天快乐的应助被xdlongchem采纳,获得10
5秒前
亳亳发布了新的文献求助10
5秒前
shayu发布了新的文献求助10
5秒前
Dentist_Gao完成签到 ,获得积分10
6秒前
mmooo完成签到 ,获得积分10
6秒前
秀秀完成签到,获得积分10
6秒前
7秒前
蜡小新完成签到,获得积分10
7秒前
姜渡完成签到 ,获得积分10
7秒前
水煮电吹风的应助被浅夏初雨采纳,获得10
7秒前
drccy的应助被xyx277采纳,获得10
7秒前
无花果的应助被微笑采纳,获得10
8秒前
斯文败类的应助被sl采纳,获得10
8秒前
XM给XM的求助进行了留言
8秒前
9秒前
9秒前
Lune7完成签到,获得积分10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180617
求助须知:如何正确求助?哪些是违规求助? 9570702
关于积分的说明 21813868
捐赠科研通 7776860
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557571
邀请新用户注册赠送积分活动 2479253